| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Effect of exchange rate changes on cash | - | - | - | 7 |
| Net earnings (loss) | -5,577 | 1,055 | 1,314 | 3,014 |
| Depreciation and amortization | 946 | 629 | 314 | 927 |
| Stock compensation expense | 146 | 94 | 59 | 181 |
| Impairment | 6,798 | 55 | 0 | 13 |
| Deferred income taxes | 13 | -116 | -27 | 14 |
| (gain) loss on divestitures, net | -10 | -10 | -10 | 103 |
| Other adjustments, net | - | -16 | -5 | 2 |
| Premium and trade receivables | 3,338 | 1,801 | 2,684 | 2,737 |
| Other assets | 245 | 543 | 669 | -78 |
| Medical claims liabilities | 3,176 | 1,809 | 1,603 | -5 |
| Unearned revenue | -5 | 21 | 208 | -58 |
| Accounts payable and accrued expenses | 2,681 | 209 | 563 | -503 |
| Other long-term liabilities | 38 | 1,857 | 814 | -84 |
| Other operating activities, net | 8 | 0 | - | 6 |
| Net cash provided by operating activities | 4,651 | 3,295 | 1,510 | 741 |
| Capital expenditures | 554 | 343 | 135 | 490 |
| Purchases of investments | 3,765 | 3,593 | 1,630 | 5,770 |
| Sales and maturities of investments | 4,131 | 2,508 | 1,236 | 4,147 |
| Divestiture proceeds, net of divested cash | 0 | 0 | 0 | 959 |
| Net cash (used in) investing activities | -188 | -1,428 | -529 | -1,154 |
| Proceeds from long-term debt | 750 | 750 | 750 | 350 |
| Payments and repurchases of long-term debt | 1,708 | 1,707 | 958 | 594 |
| Common stock repurchases | 473 | 473 | 41 | 2,181 |
| Proceeds from common stock issuances | 29 | 18 | 10 | 37 |
| Purchase of noncontrolling interest | 19 | - | - | 0 |
| Other financing activities, net | -13 | -12 | -11 | -5 |
| Net cash (used in) financing activities | -1,434 | -1,424 | -250 | -2,393 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 0 | 0 | 0 | 7 |
| Net increase (decrease) in cash, cash equivalents and restricted cash and cash equivalents | 3,029 | 443 | 731 | -2,799 |
| Cash and cash equivalents at beginning of period | 14,156 | 14,156 | 14,156 | 17,452 |
| Cash and cash equivalents at end of period | 17,185 | 14,599 | 14,887 | 14,650 |
CENTENE CORP (CNC)
CENTENE CORP (CNC)